<i>TET2</i> rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
Background: The complexity of myeloproliferative neoplasms (MPNs) cannot be characterized by acquired somatic mutations alone. Individual genetic background is thought to contribute to the development of MPNs. The aim of our study was to assess the association between the <i>TET2</i> rs1...
Main Authors: | Diana L. Lighezan, Anca S. Bojan, Mihaela Iancu, Raluca M. Pop, Ștefana Gligor-Popa, Florin Tripon, Adriana S. Cosma, Ciprian Tomuleasa, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Ioana Ioniță, Ildikó O. Gaál, Simona Vișan, Andreea-Manuela Mirea, Radu A. Popp, Mira Florea, Cătălin Araniciu, Lucian Petrescu, Ioan V. Pop, Claudia Bănescu, Adrian P. Trifa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/10/4/259 |
Similar Items
-
SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms
by: Trifa Adrian P., et al.
Published: (2020-07-01) -
The Potential Equivalents of <i>TET2</i> Mutations
by: Sergiu Pasca, et al.
Published: (2021-03-01) -
The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Monika Conchon
Published: (2011-12-01) -
Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
by: P. Akyol, et al.
Published: (2020-10-01) -
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)